Cargando…

Vitamin C-induced epigenomic remodelling in IDH1 mutant acute myeloid leukaemia

The genomes of myeloid malignancies are characterized by epigenomic abnormalities. Heterozygous, inactivating ten-eleven translocation 2 (TET2) mutations and neomorphic isocitrate dehydrogenase (IDH) mutations are recurrent and mutually exclusive in acute myeloid leukaemia genomes. Ascorbic acid (vi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mingay, M, Chaturvedi, A, Bilenky, M, Cao, Q, Jackson, L, Hui, T, Moksa, M, Heravi-Moussavi, A, Humphries, R K, Heuser, M, Hirst, M
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group 2018
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5770587/ https://www.ncbi.nlm.nih.gov/pubmed/28663574 http://dx.doi.org/10.1038/leu.2017.171

Ejemplares similares

Combination treatment of an IDH1 inhibitor with chemotherapy in IDH1 mutant acute myeloid leukemia
por: Gupta, Charu, et al.
Publicado: (2020)

The curious case of IDH mutant acute myeloid leukaemia: biochemistry and therapeutic approaches
por: Gruber, Emily, et al.
Publicado: (2023)

Synergistic activity of IDH1 inhibitor BAY1436032 with azacitidine in IDH1 mutant acute myeloid leukemia
por: Chaturvedi, Anuhar, et al.
Publicado: (2020)

Pan-mutant-IDH1 inhibitor BAY1436032 is highly effective against human IDH1 mutant acute myeloid leukemia in vivo
por: Chaturvedi, A, et al.
Publicado: (2017)

Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia
por: Bassal, Mahmoud A., et al.
Publicado: (2022)

Author Correction: Germline mutations in mitochondrial complex I reveal genetic and targetable vulnerability in IDH1-mutant acute myeloid leukaemia
por: Bassal, Mahmoud A., et al.
Publicado: (2022)

Concurrent inhibition of IDH and methyltransferase maximizes therapeutic efficacy in IDH mutant acute myeloid leukemia
por: Zeng, Zhihong, et al.
Publicado: (2021)

Cup‐like blasts in acute myeloid leukaemia with NPM1 and IDH2 mutations
por: Ohya, Eiko, et al.
Publicado: (2021)

Preclinical efficacy against acute myeloid leukaemia of SH1573, a novel mutant IDH2 inhibitor approved for clinical trials in China
por: Wang, Zhiqiang, et al.
Publicado: (2021)

Polycomb contraction differentially regulates terminal human hematopoietic differentiation programs
por: Lorzadeh, A., et al.
Publicado: (2022)

Epigenomic programming in early fetal brain development
por: Li, Luolan, et al.
Publicado: (2020)

Methylation and transcription patterns are distinct in IDH mutant gliomas compared to other IDH mutant cancers
por: Unruh, Dusten, et al.
Publicado: (2019)

Mitochondrial metabolism supports resistance to IDH mutant inhibitors in acute myeloid leukemia
por: Stuani, Lucille, et al.
Publicado: (2021)

IDH1-mutant cancer cells are sensitive to cisplatin and an IDH1-mutant inhibitor counteracts this sensitivity
por: Khurshed, Mohammed, et al.
Publicado: (2018)

Mutant allelic burden in acute myeloid leukaemia: Why bother?
por: Touw, Ivo P., et al.
Publicado: (2019)

Immuno-phenotyping of IDH-mutant grade 3 astrocytoma and IDH-wildtype glioblastoma reveals specific differences in cells of myeloid origin
por: Raghavan, Jayashree V., et al.
Publicado: (2021)

Therapies for IDH-Mutant Gliomas
por: Alshiekh Nasany, Ruham, et al.
Publicado: (2023)

Induction of sarcomas by mutant IDH2
por: Lu, Chao, et al.
Publicado: (2013)

IDH1/IDH2 Inhibition in Acute Myeloid Leukemia
por: Cerchione, Claudio, et al.
Publicado: (2021)

Molecular Imaging of Metabolic Reprograming in Mutant IDH Cells
por: Viswanath, Pavithra, et al.
Publicado: (2016)

Postoperative risk of IDH-mutant glioma–associated seizures and their potential management with IDH-mutant inhibitors
por: Drumm, Michael R., et al.
Publicado: (2023)

Targeted therapy with the mutant IDH2 inhibitor enasidenib for high-risk IDH2-mutant myelodysplastic syndrome
por: DiNardo, Courtney D., et al.
Publicado: (2022)

Retrospective examination of pseudoprogression in IDH mutant gliomas
por: Wetzel, Ethan A, et al.
Publicado: (2023)

Epigenetic and functional changes imposed by NUP98-HOXA9 in a genetically engineered model of chronic myeloid leukemia progression
por: Sloma, Ivan, et al.
Publicado: (2020)

Desacetylmethylcolchicine in the Treatment of Myeloid Leukaemia
por: Jelliffe, A. M., et al.
Publicado: (1956)

Metabolic Reprogramming in Mutant IDH1 Glioma Cells
por: Izquierdo-Garcia, Jose L., et al.
Publicado: (2015)

In vivo efficacy of mutant IDH1 inhibitor HMS-101 and structural resolution of distinct binding site
por: Chaturvedi, Anuhar, et al.
Publicado: (2019)

Genomic profiles of IDH-mutant gliomas: MYCN-amplified IDH-mutant astrocytoma had the worst prognosis
por: Lee, Kwanghoon, et al.
Publicado: (2023)

Discovery of AG-120 (Ivosidenib): A First-in-Class Mutant IDH1 Inhibitor for the Treatment of IDH1 Mutant Cancers
por: Popovici-Muller, Janeta, et al.
Publicado: (2018)

Mismatch repair protein mutations in isocitrate dehydrogenase (IDH)-mutant astrocytoma and IDH-wild-type glioblastoma
por: Richardson, Timothy E, et al.
Publicado: (2023)

Oligosarcomas, IDH-mutant are distinct and aggressive
por: Suwala, Abigail K., et al.
Publicado: (2021)

Mutant IDH1 is required for IDH1 mutated tumor cell growth
por: Jin, Genglin, et al.
Publicado: (2012)

Deep Learning Can Differentiate IDH-Mutant from IDH-Wild GBM
por: Pasquini, Luca, et al.
Publicado: (2021)

Early volumetric, perfusion, and diffusion MRI changes after mutant isocitrate dehydrogenase (IDH) inhibitor treatment in IDH1-mutant gliomas
por: Cho, Nicholas S, et al.
Publicado: (2022)

Insulator dysfunction and oncogene activation in IDH mutant gliomas
por: Flavahan, William A., et al.
Publicado: (2015)

Wnt Signalling in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Metabolic characterization of isocitrate dehydrogenase (IDH) mutant and IDH wildtype gliomaspheres uncovers cell type-specific vulnerabilities
por: Garrett, Matthew, et al.
Publicado: (2018)

'Lot's Wife' Syndrome in Acute Myeloid Leukaemia
por: Barnett, M. M.
Publicado: (1984)

Haploinsufficiency of NFKBIA reshapes the epigenome antipodal to the IDH mutation and imparts disease fate in diffuse gliomas
por: Bredel, Markus, et al.
Publicado: (2023)

Adhesion Deregulation in Acute Myeloid Leukaemia
por: Gruszka, Alicja M., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_qbrnjngrh422bdcn4ffhagjern